Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

AKTX

Akari Therapeutics Plc ADR

Apr 16 • 04:00PM ET

1.16

Dollar change -0.04
Percentage change -3.71	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	0.40%	Shs Outstand	6.62M	Perf Week	-12.13%
Market Cap	7.65M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	6.59M	Perf Month	-41.35%
Income	-9.95M	PEG	-	EPS next Q	-	Inst Own	4.41%	Short Float	0.16%	Perf Quarter	-60.02%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.82	Perf Half Y	-67.99%
Book/sh	-0.03	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.01M	Perf Year	-66.01%
Cash/sh	0.58	P/C	1.99	EPS next 5Y	-	ROE	-	52W Range	1.10 - 5.50	Perf YTD	-62.96%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-78.99%	Beta	1.04
Dividend TTM	-	Quick Ratio	0.95	Sales past 5Y	0.00%	Gross Margin	-	52W Low	5.05%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	0.95	EPS Y/Y TTM	13.28%	Oper. Margin	0.00%	RSI (14)	22.40	Volatility	11.97% 10.55%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	80.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	15.04%	Payout	-	Rel Volume	1.13	Prev Close	1.20
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Apr 01 BMO	Avg Volume	12.87K	Price	1.16
SMA20	-27.63%	SMA50	-43.11%	SMA200	-62.88%	Trades		Volume	14,524	Change	-3.71%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-04-19	Upgrade	B. Riley FBR	Neutral → Buy	$2.50 → $3
Feb-08-18	Initiated	B. Riley FBR, Inc.	Neutral	$3
Sep-22-17	Upgrade	William Blair	Mkt Perform → Outperform
May-31-17	Upgrade	Chardan Capital Markets	Sell → Neutral	$6
Apr-17-17	Reiterated	Chardan Capital Markets	Sell	$6.50 → $5
Jul-11-16	Initiated	Chardan Capital Markets	Sell	$5

Apr-15-24 08:00AM	Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 (GlobeNewswire)
Apr-01-24 06:30AM	Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights (GlobeNewswire) -19.03%
Mar-08-24 04:38PM	Kuehn Law Encourages VIVK, HES, SDPI, and AKTX Investors to Contact Law Firm (GlobeNewswire)
Mar-05-24 08:00AM	Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit (GlobeNewswire)
Jan-02-24 08:00AM	Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing (GlobeNewswire) -7.16%
08:00AM	Loading…
Dec-14-23 08:00AM	Akari Therapeutics to Present at Biotech Showcase 2024 (GlobeNewswire) +5.84%
Dec-01-23 08:00AM	Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors (GlobeNewswire) +9.49%
Nov-16-23 08:00AM	Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference (GlobeNewswire)
Nov-06-23 08:00AM	Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference (GlobeNewswire)
Oct-04-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now (GlobeNewswire) -5.21%
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire) +6.30%
Sep-29-23 08:00AM	Akari Therapeutics Reports First Half 2023 Financial Results and Highlights (GlobeNewswire)
Sep-27-23 08:00AM	Akari Therapeutics to Present at Emerging Growth Conference (GlobeNewswire)
Sep-21-23 08:00AM	Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit (GlobeNewswire)
Sep-19-23 08:00AM	Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs (GlobeNewswire)
08:00AM	Loading…
Sep-05-23 08:00AM	Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -6.59%
Aug-21-23 02:01PM	British pharma opens U.S. headquarters in Boston (American City Business Journals)
Aug-18-23 08:00AM	Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials (GlobeNewswire) +10.00%
Aug-15-23 08:00AM	Akari Therapeutics, Plc Announces ADS Ratio Change (GlobeNewswire) -21.20%
Aug-02-23 08:00AM	Akari Therapeutics Announces the Appointment of Beth-Anne Lang as Senior Vice President, Regulatory Affairs (GlobeNewswire)
Aug-01-23 07:30AM	Here's Why Akari Therapeutics (NASDAQ:AKTX) Must Use Its Cash Wisely (Simply Wall St.) +7.13%
Jul-27-23 08:00AM	Akari Therapeutics Granted Nomacopan Orphan Drug Designation from the European Commission for Treatment in Hematopoietic Stem Cell Transplantation (GlobeNewswire) +7.94%
Jul-19-23 08:00AM	Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer (GlobeNewswire)
Jul-13-23 08:00AM	Akari Therapeutics Provides Updates on Development of Nomacopan in Pediatric and Adult HSCT-TMA (GlobeNewswire) +6.15%
Jul-11-23 08:00AM	Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy (GlobeNewswire)
Jul-06-23 08:00AM	Akari Therapeutics Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Nomacopan for Treatment in Hematopoietic Stem Cell Transplantation (GlobeNewswire)
Jul-05-23 08:00AM	Akari Therapeutics Appoints Industry Veteran Wael Hashad to Board of Directors (GlobeNewswire)
May-16-23 04:05PM	Aspira Womens Health Names Torsten Hombeck as Chief Financial Officer (GlobeNewswire)
08:00AM	Akari Therapeutics to Participate in A.G.P.s Virtual Healthcare Conference (GlobeNewswire)
May-01-23 08:00AM	Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights (GlobeNewswire)
04:15PM	Loading…
Apr-25-23 04:15PM	Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement (GlobeNewswire) +6.31%
Apr-19-23 02:01PM	Insiders rewarded with a US$607k addition on top of their US$1.3m purchase as Akari Therapeutics, Plc (NASDAQ:AKTX) hits US$22m (Simply Wall St.)
Apr-14-23 08:00AM	Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs (GlobeNewswire) +5.26%
Apr-11-23 08:00AM	Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology (GlobeNewswire)
Apr-03-23 08:00AM	Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting (GlobeNewswire) +12.00%
Mar-30-23 09:09AM	Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering (GlobeNewswire) -16.34%
Mar-29-23 08:00AM	Poland and U.K. Regulatory Authorities URPL and MHRA Approve Use of New, Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Study (GlobeNewswire) -5.23%
Feb-21-23 08:00AM	Akari Therapeutics Announces Presentation of a Case Study from Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA as a Late-Breaker at The Transplantation & Cellular Therapy Tandem Meetings (GlobeNewswire) -10.88%
Feb-15-23 08:00AM	Akari Therapeutics Announces Pre-Clinical Development Progress Toward Potential IND on Long-Acting PAS-Nomacopan for Geographic Atrophy (GA) (GlobeNewswire)
Feb-13-23 08:00AM	Akari Therapeutics Announces Acceleration of the Phase 3 Clinical Trial of Nomacopan for Treatment of Pediatric HSCT-TMA into Pivotal Part B and Addition of a New Pipeline Program Developing Nomacopan for HSCT-TMA in Adults (GlobeNewswire)
Jan-04-23 08:00AM	Akari Therapeutics to Present at Biotech Showcase 2023 (GlobeNewswire) +5.09%
Dec-01-22 08:00AM	Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference (GlobeNewswire)
Nov-22-22 08:00AM	Akari Therapeutics to Participate in the Ophthalmology Day at BTIG (GlobeNewswire)
Nov-10-22 08:00AM	Akari Therapeutics Granted FDA Rare Pediatric Disease Designation of Nomacopan for the Treatment of Pediatric HSCT-TMA (GlobeNewswire) +5.88%
Nov-09-22 08:00AM	Akari Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) +8.51%
Nov-08-22 03:40PM	Sidoti's November Micro-Cap Virtual Conference (ACCESSWIRE)
08:00AM	Akari Therapeutics Announces the Appointment of John F. Neylan, III, MD as Executive Vice President, Chief Medical Officer (GlobeNewswire)
Oct-31-22 08:00AM	Akari Therapeutics to Participate in the Sidoti November 2022 Virtual Micro-Cap Conference (GlobeNewswire)
Oct-28-22 04:30PM	Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification (GlobeNewswire)
Sep-27-22 08:00AM	Akari Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Pipeline Progress (GlobeNewswire)
Sep-22-22 08:00AM	Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference (GlobeNewswire)
Sep-12-22 08:00AM	Akari Therapeutics Announces $12.75 Million Registered Direct Offering (GlobeNewswire) -27.88%
Sep-08-22 06:48AM	One Akari Therapeutics, Plc (NASDAQ:AKTX) insider upped their stake by 180% in the previous year (Simply Wall St.) -9.01%
Aug-01-22 08:00AM	Akari Therapeutics Narrows Pipeline Focus (GlobeNewswire) +5.26%
Jul-29-22 09:36AM	Will Akari Therapeutics (NASDAQ:AKTX) Spend Its Cash Wisely? (Simply Wall St.) +15.42%
Jul-28-22 08:00AM	Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy (GlobeNewswire)
Jul-20-22 06:00AM	Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress (GlobeNewswire)
Jul-07-22 08:00AM	Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) (GlobeNewswire) +9.47%
Jun-13-22 07:00AM	Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies (GlobeNewswire)
May-19-22 04:05PM	Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting (GlobeNewswire) -7.63%
May-16-22 06:00AM	Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress (GlobeNewswire)
May-11-22 07:00AM	Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting (GlobeNewswire) -5.04%
May-10-22 07:00AM	Akari Therapeutics Announces Publication of Phase II Data of Investigational Nomacopan for the Treatment of Bullous Pemphigoid (BP) in JAMA Dermatology (GlobeNewswire) +5.31%
May-09-22 07:00AM	Akari Presents Results from Two Preclinical Development Programs of Long-Acting PAS-Nomacopan in Geographic Atrophy (GA) Dry Age-Related Macular Degeneration and Nomacopan in Experimental Immune-Mediated Conjunctival Disease (EIC) (GlobeNewswire)
Mar-21-22 08:00AM	Akari Therapeutics to Present on Two Ongoing Programs Covering Age-Related Macular Degeneration and Diseases of the Surface of the Eye at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting (GlobeNewswire)
Mar-09-22 07:30AM	Akari Therapeutics Announces New Data Supporting Use of Drug Candidate Votucalis Targeting Difficult to Treat Pain and Itch (GlobeNewswire)
Mar-08-22 11:45AM	Akari Therapeutics, Plc Announces $9.0 Million Registered Direct Offering (GlobeNewswire) -9.69%
Mar-05-22 07:02AM	One Akari Therapeutics, Plc (NASDAQ:AKTX) insider upped their stake by 180% in the previous year (Simply Wall St.)
Mar-02-22 07:00AM	Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer (GlobeNewswire)
Feb-28-22 09:12AM	Akari Therapeutics Announces New Data Showing A Significant Role for Complement Activation in the Clinical Outcomes of U.S. Army Trauma Patients in Iraq and the Therapeutic Potential of Nomacopan for Treatment of Trauma (GlobeNewswire)
Feb-11-22 07:00AM	Akari Therapeutics to Present at BIO CEO & Investor Conference (GlobeNewswire) +9.77%
Jan-26-22 08:30AM	Akari Advances Lung Program with Inhaled Nomacopan Focused on Early Treatment of Severe Exacerbations in Lung Diseases (GlobeNewswire) +5.26%
Jan-19-22 08:30AM	FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies (GlobeNewswire)
Jan-04-22 07:00AM	Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire)
Dec-30-21 11:03AM	Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering (GlobeNewswire) -6.76%
Dec-05-21 06:13AM	We Think Akari Therapeutics (NASDAQ:AKTX) Needs To Drive Business Growth Carefully (Simply Wall St.)
Dec-03-21 07:45AM	Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progress (GlobeNewswire)
Dec-01-21 08:30AM	Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders (GlobeNewswire)
Oct-26-21 08:00AM	Akari Therapeutics Announces Presentation at Annual Complement-Based Drug Development Summit (GlobeNewswire)
Oct-25-21 08:30AM	Akari Therapeutics Announces New Data with Nomacopan from its Surface of the Eye Program (GlobeNewswire)
Sep-22-21 09:00AM	Akari Therapeutics to Present at the Cantor Virtual Global Healthcare Conference (GlobeNewswire)
08:30AM	Akari Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Clinical Progress (GlobeNewswire)
Sep-10-21 08:30AM	Akari Therapeutics to Present Its Phase III Plans for Nomacopan in Patients with Bullous Pemphigoid at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium (GlobeNewswire)
Sep-07-21 07:00AM	Akari Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Jul-07-21 09:15AM	Akari Therapeutics Announces Private Placement (GlobeNewswire)
Jun-29-21 04:01PM	Akari Therapeutics Reports Q1 2021 Financial Results and Highlights Recent Clinical Progress (GlobeNewswire)
Apr-28-21 10:25AM	Akari Therapeutics' Nomacopan Secures Expediated Review Tag For Blistering Skin Disorder (Benzinga)
08:00AM	Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid (GlobeNewswire)
Apr-22-21 07:30AM	Akari Therapeutics Announces Poster Presentation of Phase II Bullous Pemphigoid Disease and Phase III Trial Design at American Academy of Dermatology Association Virtual Meeting Experience (GlobeNewswire)
Apr-20-21 06:40PM	Akari Therapeutics Reports Full Year 2020 Financial Results and Highlights Recent Clinical Progress (GlobeNewswire)
Apr-12-21 12:48PM	Akari Therapeutics' To Go With Pivotal Bullous Pemphigoid Study With Nomacopan (Benzinga) -5.81%
10:16AM	Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP) (GlobeNewswire)
Mar-04-21 08:30AM	Akari Therapeutics Announces a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR) for Nomacopan in Trauma (GlobeNewswire)
Feb-25-21 01:41PM	Akari Therapeutics' PASylated Nomacopan Shows Promising Action In Animal Studies (Benzinga)
09:07AM	Akari Therapeutics Presents New Preclinical Data Highlighting Potential of Long-Acting PASylated Nomacopan to Treat Retinal Diseases, Including Age-Related Macular Degeneration (AMD) and Uveitis (GlobeNewswire)
Feb-01-21 11:26PM	Is Akari Therapeutics, Plc (NASDAQ:AKTX) Popular Amongst Insiders? (Simply Wall St.)
09:29AM	Akari Therapeutics Adds Histamine Inhibitor Votucalis to Pipeline to treat Neuropathic Pain and Dermatological Disease (GlobeNewswire)
Jan-06-21 09:32AM	Akari Therapeutics to Participate in Two January Virtual Investor Conferences (GlobeNewswire)
Dec-11-20 09:00AM	Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress (GlobeNewswire) +5.26%
08:55AM	Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) (GlobeNewswire)

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in Boston, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AKTX

Akari Therapeutics Plc ADR

Upgrade your FINVIZ experience